PURPOSE: The purposes of this study were to investigate the efficacy of radiocolloid lymphoscintigraphy and of handheld gamma probe procedure for sentinel lymph node biopsy (SLNB) in papillary thyroid carcinoma (PTC) and to evaluate its results in clinical staging. MATERIALS AND METHODS: Sixty-five PTC consecutive patients entered the study. Patients underwent radiocolloid lymphoscintigraphy before surgery. Intraoperative sentinel lymph node (SLN) localization was performed using a handheld gamma probe. They were followed up at 2, 6 months, and yearly. RESULTS: SLN metastases were diagnosed in 52%. Fifty-one patients underwent ablative 131-I therapy. The mean Tireoglobulin level in N0 vs N1 cases was 2.2 ng/ml vs 4.73 (p = 0.03) and 0.68 vs 2.1 ng/ml (p = 0.005) before and after 131-I therapy, respectively. CONCLUSIONS: In patients classified N0 by SLNB, ablative 131-I therapy could be avoided.
PURPOSE: The purposes of this study were to investigate the efficacy of radiocolloid lymphoscintigraphy and of handheld gamma probe procedure for sentinel lymph node biopsy (SLNB) in papillary thyroid carcinoma (PTC) and to evaluate its results in clinical staging. MATERIALS AND METHODS: Sixty-five PTC consecutive patients entered the study. Patients underwent radiocolloid lymphoscintigraphy before surgery. Intraoperative sentinel lymph node (SLN) localization was performed using a handheld gamma probe. They were followed up at 2, 6 months, and yearly. RESULTS: SLN metastases were diagnosed in 52%. Fifty-one patients underwent ablative 131-I therapy. The mean Tireoglobulin level in N0 vs N1 cases was 2.2 ng/ml vs 4.73 (p = 0.03) and 0.68 vs 2.1 ng/ml (p = 0.005) before and after 131-I therapy, respectively. CONCLUSIONS: In patients classified N0 by SLNB, ablative 131-I therapy could be avoided.
Authors: M Catarci; F Zaraca; R Angeloni; B Mancini; M G de Filippo; R Massa; M Carboni; G Pasquini Journal: J Surg Oncol Date: 2001-05 Impact factor: 3.454
Authors: D Rubello; C Nanni; I Merante Boschin; A Toniato; A Piotto; L Rampin; G Mariani; A Al-Nahhas; M R Pelizzo Journal: J Exp Clin Cancer Res Date: 2006-12
Authors: M R Pelizzo; A Toniato; N Sorgato; A Losi; F Torresan; I Merante Boschin Journal: Acta Otorhinolaryngol Ital Date: 2009-12 Impact factor: 2.124
Authors: R Gelmini; M Campanelli; F Cabry; A Franceschetto; G Ceresini; L Ruffini; A Zaccaroni; P Del Rio Journal: J Endocrinol Invest Date: 2017-08-31 Impact factor: 4.256